Devyser Diagnostics AB (publ)

OM:DVYSR Stock Report

Market Cap: SEK 2.2b

Devyser Diagnostics Valuation

Is DVYSR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DVYSR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 448.23
Fair Value
70.2% undervalued intrinsic discount
4
Number of Analysts

Below Fair Value: DVYSR (SEK133.5) is trading below our estimate of fair value (SEK448.23)

Significantly Below Fair Value: DVYSR is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DVYSR?

Key metric: As DVYSR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for DVYSR. This is calculated by dividing DVYSR's market cap by their current revenue.
What is DVYSR's PS Ratio?
PS Ratio11.1x
SalesSEK 198.10m
Market CapSEK 2.20b

Price to Sales Ratio vs Peers

How does DVYSR's PS Ratio compare to its peers?

The above table shows the PS ratio for DVYSR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average23.9x
EGTX Egetis Therapeutics
32.2x91.5%SEK 2.2b
HNSA Hansa Biopharma
10.2x40.4%SEK 1.7b
CRNO B Cereno Scientific
16.3x-11.4%SEK 1.4b
SANION Saniona
37x38.0%SEK 985.7m
DVYSR Devyser Diagnostics
11.1x31.3%SEK 2.2b

Price-To-Sales vs Peers: DVYSR is good value based on its Price-To-Sales Ratio (11.1x) compared to the peer average (23.9x).

Price to Sales Ratio vs Industry

How does DVYSR's PS Ratio compare vs other companies in the SE Biotechs Industry?

9 CompaniesPrice / SalesEstimated GrowthMarket Cap
XBRANE Xbrane Biopharma
1.4x58.0%US$25.48m
SPRINT Sprint Bioscience
1.8x27.6%US$9.92m
GEAN Genetic Analysis
1.4xn/aUS$2.41m
ATORX Alligator Bioscience
0.4xn/aUS$2.11m
DVYSR 11.1xIndustry Avg. 13.7xNo. of Companies9PS01224364860+
9 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: DVYSR is good value based on its Price-To-Sales Ratio (11.1x) compared to the Swedish Biotechs industry average (14.2x).

Price to Sales Ratio vs Fair Ratio

What is DVYSR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DVYSR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio11.1x
Fair PS Ratio7.1x

Price-To-Sales vs Fair Ratio: DVYSR is expensive based on its Price-To-Sales Ratio (11.1x) compared to the estimated Fair Price-To-Sales Ratio (7.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DVYSR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 133.50
SEK 164.95
+23.6%
10.9%SEK 192.12SEK 142.06n/a4
Feb ’26SEK 129.50
SEK 164.95
+27.4%
10.9%SEK 192.12SEK 142.06n/a4
Jan ’26SEK 118.50
SEK 158.68
+33.9%
13.1%SEK 192.09SEK 139.92n/a4
Dec ’25SEK 130.00
SEK 158.61
+22.0%
13.1%SEK 191.94SEK 140.05n/a4
Nov ’25SEK 138.50
SEK 156.93
+13.3%
14.1%SEK 192.01SEK 136.07n/a4
Oct ’25SEK 128.50
SEK 157.74
+22.8%
14.6%SEK 191.68SEK 133.45n/a4
Sep ’25SEK 113.50
SEK 128.66
+13.4%
3.1%SEK 134.20SEK 125.04n/a3
Aug ’25SEK 112.50
SEK 131.40
+16.8%
2.3%SEK 134.40SEK 128.39n/a2
Jul ’25SEK 110.00
SEK 121.86
+10.8%
1.6%SEK 123.76SEK 119.96n/a2
Jun ’25SEK 104.50
SEK 126.39
+20.9%
1.3%SEK 128.05SEK 124.74n/a2
May ’25SEK 98.80
SEK 129.04
+30.6%
3.2%SEK 133.22SEK 124.86n/a2
Apr ’25SEK 101.50
SEK 115.44
+13.7%
10.8%SEK 127.97SEK 98.41n/a3
Mar ’25SEK 91.00
SEK 113.51
+24.7%
10.6%SEK 127.97SEK 98.40n/a3
Feb ’25SEK 89.40
SEK 114.10
+27.6%
9.1%SEK 126.46SEK 100.99SEK 129.503
Jan ’25SEK 78.60
SEK 114.10
+45.2%
9.1%SEK 126.46SEK 100.99SEK 118.503
Dec ’24SEK 73.60
SEK 114.10
+55.0%
9.1%SEK 126.46SEK 100.99SEK 130.003
Nov ’24SEK 60.60
SEK 117.08
+93.2%
9.6%SEK 131.86SEK 104.50SEK 138.503
Oct ’24SEK 65.20
SEK 117.08
+79.6%
9.6%SEK 131.86SEK 104.50SEK 128.503
Sep ’24SEK 73.00
SEK 117.44
+60.9%
9.4%SEK 130.88SEK 103.72SEK 113.503
Aug ’24SEK 78.00
SEK 123.44
+58.3%
13.1%SEK 146.07SEK 109.47SEK 112.503
Jul ’24SEK 77.20
SEK 122.44
+58.6%
12.8%SEK 144.33SEK 108.17SEK 110.003
Jun ’24SEK 78.20
SEK 122.44
+56.6%
12.8%SEK 144.33SEK 108.17SEK 104.503
May ’24SEK 86.40
SEK 109.85
+27.1%
9.7%SEK 124.63SEK 99.89SEK 98.803
Apr ’24SEK 71.12
SEK 109.85
+54.5%
9.7%SEK 124.63SEK 99.89SEK 101.503
Mar ’24SEK 79.00
SEK 109.04
+38.0%
9.6%SEK 123.35SEK 98.86SEK 91.003
Feb ’24SEK 71.44
SEK 119.03
+66.6%
3.5%SEK 123.14SEK 114.92SEK 89.402
Analyst Price Target
Consensus Narrative from 4 Analysts
SEK 164.95
Fair Value
19.1% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 13:56
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Devyser Diagnostics AB (publ) is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Erik HultgårdCarnegie Investment Bank AB
Ludvig LundgrenNordea Markets
Filip WibergPareto Securities